目的： 探讨过继免疫治疗联合放化疗与单纯放化疗相比对非小细胞肺癌（non-small cell lung cancer，NSCLC）患者疗效的差异。 方法: 通过检索PubMed、Medline、EMBASE、Cochrane 数据库、中国期刊全文数据库和维普中文数据库，收集1995年1月至2012年9月发表的符合要求的随机化对照试验（randomized controlled trial，RCT）或非随机同期对照试验（non-randomized concurrent controlled trail，NRCCT），应用Revman5.0软件进行数据分析。 结果： 共纳入10项研究，共计1 326名患者。Meta分析结果显示：与单纯放化疗相比，过继免疫治疗联合放化疗能够提高患者2年无进展生存（progression-free survival，PFS）（OR=2.20，95%CI：1.44~3.36，P=0.0003）和2年总生存（OR=2.69，95%CI：1.92~3.78，P<0.00001）。接受过继免疫治疗后，早期和进展期NSCLC患者都能得到较大的获益\[（OR=3.24（1.65~6.35）；OR=2.86（1.37~5.98）\]。过继免疫治疗引起的不良反应多呈自限性，主要有发热、寒战、恶心、乏力等，未观察到严重毒性反应。 结论： 过继免疫治疗联合放化疗能延缓NSCLC复发，提高患者生存期，且早期患者接受免疫治疗获益更显著。

Objective: To systematically assess the therapeutic effectiveness of adoptive immunotherapy combined with chemo/radio therapy compared with chemo/radio therapy alone in non-small cell lung cancer (NSCLC) patients. Methods: A systematic search of Pubmed, Medline, EMBASE, Cochrane Library, CNKI and VIP database from January 1995 to September 2012 was performed to identify the eligible randomized controlled trials (RCTs) and non-randomized concurrent controlled trails (NRCCTs). The improper documents were excluded. The soft-ware Revman5.0 was used for data synthesis. Results: A total of 10 studies involving 1 326 patients were identified. The result of Meta-analyses showed that adoptive immunotherapy combined with radio/chemo therapy improved the 2-year progression-free survival (PFS) (OR=2.20, 95%CI：1.44-3.36, P=0.0003) and 2-year overall survival (OR=2.69, 95%CI：1.92-3.78, P<000001). Both early-stage and advanced NSCLC patients benefited from adoptive immunotherapy (OR=3.24\[1.65-6.35\]; OR=2.86\[1.37-5.98\]). The adverse events were self limiting, including fever, chill, nausea, and fatigue. No severe toxicity was observed. Conclusion: Adoptive immunotherapy combined with chemo/radio therapy can decrease the risk of recurrence and improve the overall survival of NSCLC patients; early-stage patients receiving adoptive immunotherapy may benefit more.

国家重点基础研究发展计划（973 计划）资助项目（No. 2012CB9333004）；国家高技术研究发展计划（863计划）资助项目（No. SS2012AA020403）；肿瘤医院临床试验专项基金资助项目（No. 11L01）